(29) reported that increased CD4+ and CD8+ terminal effector memory T cells were associated with the response to nivolumab in patients with head and neck squamous cell carcinoma, while another study suggested that the decrease in CD4+ T cells after the first dose of ICIs was a poor predictor for OS and tumor progression (30). The gene discussed is CD8A; the disease is head and neck squamous cell carcinoma.